Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) announced today the launch of a new oncology panel on its next generation sequencing (NGS) platform. The IntelliGEN assay improves sensitivity and detection rates for somatic mutations in cancer, assessing approximately 2600 mutations within 50 oncogenes/tumor suppressor genes. IntelliGEN will be available through Integrated Oncology, a member of the LabCorp Specialty Testing Group.
Cancer treatment has shifted in recent years to the use of biologic therapeutics that target genomic alterations in cancers, creating demand for more advanced and sensitive genomic testing to identify these alterations. These new tests must provide more diagnostically significant information and, due to the earlier detection of some cancers, must correctly identify mutations present in smaller samples. LabCorp's NGS platform meets both of these demands, providing tests that reliably detect the presence of many different somatic mutations, even if in just a fraction of the cells that are assayed.
Integrated Oncology’s IntelliGEN assay provides an assessment of targetable mutations within a panel profile of 50 cancer genes known to be involved in the development, progression and/or treatment of cancers. Included in the panel are well-established biomarkers that may direct therapeutic decisions. IntelliGEN may be useful as a tool in multiple clinical settings, including when guideline-recommended biomarker evaluation yields no targeted therapeutic option, when relapse or disease progression has occurred after prior therapies, when the tumor is poorly differentiated and of uncertain origin, when the cancer lacks an effective standard-of-care therapy at the time of diagnosis, when there is limited tissue to perform guideline-recommended biomarker evaluation or when a broad profile of potential gene targets for future clinical trials would be useful.
“Integrated Oncology’s IntelliGEN assay provides an assessment of targetable mutations within a panel profile of 50 cancer genes known to be involved in the development, progression and treatment of cancers,” stated Dr. Mark Brecher, LabCorp's Chief Medical Officer. “LabCorp continues to introduce new tests and technologies to give healthcare providers the actionable information necessary for making appropriate diagnosis and treatment decisions.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts